Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Harmony Biosciences Holdings ( (HRMY) ) has issued an announcement.
On April 14, 2026, Harmony Biosciences announced that Chief Financial Officer Sandip Kapadia stepped down the same day, with a separation agreement providing severance in exchange for customary releases and covenants. The company simultaneously appointed veteran biopharmaceutical executive Glenn Reicin as CFO, granting him a $500,000 base salary, performance-based bonus opportunity, equity awards, and change-in-control protections, while reiterating its 2026 WAKIX net revenue guidance of $1.0–$1.04 billion and signaling continued focus on strategic growth, capital markets execution, and long-term value creation for shareholders.
Reicin brings extensive experience from prior CFO and operating roles at Eccogene, Alladapt Immunotherapeutics, and Sigilon Therapeutics, as well as a long tenure as a top-ranked Morgan Stanley medical technology analyst, and will oversee finance, investor relations, and risk management at Harmony. Management framed the leadership transition as occurring at a pivotal moment, emphasizing the company’s strong balance sheet, solid commercial execution, and ambitions to leverage its financial position and pipeline to sustain growth and enhance shareholder value in the rare neurology segment.
The most recent analyst rating on (HRMY) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Harmony Biosciences Holdings stock, see the HRMY Stock Forecast page.
Spark’s Take on HRMY Stock
According to Spark, TipRanks’ AI Analyst, HRMY is a Outperform.
Overall score is driven primarily by strong fundamentals (profitability, improving balance sheet strength) and supportive earnings-call outlook (reiterated blockbuster 2026 guidance and pipeline catalysts). This is tempered by a weak technical setup (below key moving averages with negative MACD) and a notable near-term cash-flow visibility concern from the TTM cash flow print.
To see Spark’s full report on HRMY stock, click here.
More about Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Founded in 2017 and headquartered in Plymouth Meeting, Pa., the company’s growth strategy centers on its flagship product WAKIX and building a broader pipeline in rare neurology.
Average Trading Volume: 865,554
Technical Sentiment Signal: Sell
Current Market Cap: $1.67B
Find detailed analytics on HRMY stock on TipRanks’ Stock Analysis page.